1. First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. (10th January 2017) Authors: Glatt, Sophie; Helmer, Eric; Haier, Birgit; Strimenopoulou, Foteini; Price, Graham; Vajjah, Pavan; Harari, Olivier A.; Lambert, John; Shaw, Stevan Journal: British journal of clinical pharmacology Issue: Volume 83:Number 5(2017:May) Page Start: 991 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. Issue 111 (July 2020) Authors: Chen, Sijia; Paveley, Ross; Kraal, Lianne; Sritharan, Lathees; Stevens, Elizabeth; Dedi, Neesha; Shock, Anthony; Shaw, Stevan; Juarez, Maria; Yeremenko, Nataliya; Baeten, Dominique; Payne, Andrew Journal: Journal of autoimmunity Issue: Issue 111(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0302 MUCOSAL-ASSOCIATED INVARIANT T (MAIT)-CELL-DERIVED IL-17A AND IL-17F PRODUCTION IS IL-23-INDEPENDENT AND BIASED TOWARDS IL-17F. (June 2019) Authors: Cole, Suzanne; Simpson, Catherine; Okoye, Remi; Griffiths, Meryn; Baeten, Dominique; Shaw, Stevan; Maroof, Ash Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. Issue 7 (3rd October 2018) Authors: Smith, Bryan; Kiessling, Andrea; Lledo-Garcia, Rocio; Dixon, Kate L.; Christodoulou, Louis; Catley, Matthew C.; Atherfold, Paul; D'Hooghe, Lena E.; Finney, Helene; Greenslade, Kevin; Hailu, Hanna; Kevorkian, Lara; Lightwood, Daniel; Meier, Christoph; Munro, Rebecca; Qureshi, Omar; Sarkar, Kaushik... Journal: MAbs Issue: Volume 10:Issue 7(2018) Page Start: 1111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 02.13 Il-17f contributes to human chronic inflammation in synovial tissue: Preclinical evidence with dual il-17a and il-17f inhibition with bimekizumab in psoriatic arthritis. (1st March 2017) Authors: Maroof, Ash; Baeten, Dominique; Archer, Sophie; Griffiths, Meryn; Shaw, Stevan Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 1 Page Start: A13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Issue 4 (23rd December 2017) Authors: Glatt, Sophie; Baeten, Dominique; Baker, Terry; Griffiths, Meryn; Ionescu, Lucian; Lawson, Alastair D G; Maroof, Ash; Oliver, Ruth; Popa, Serghei; Strimenopoulou, Foteini; Vajjah, Pavan; Watling, Mark I L; Yeremenko, Nataliya; Miossec, Pierre; Shaw, Stevan Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 4(2018) Page Start: 523 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Issue 8 (8th August 2019) Authors: Glatt, Sophie; Taylor, Peter C; McInnes, Iain B; Schett, Georg; Landewé, Robert; Baeten, Dominique; Ionescu, Lucian; Strimenopoulou, Foteini; Watling, Mark I L; Shaw, Stevan Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 8(2019) Page Start: 1033 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and pharmacokinetics of olokizumab, an anti‐IL‐6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Issue 5 (26th May 2014) Authors: Kretsos, Kosmas; Golor, Georg; Jullion, Astrid; Hickling, Matthew; McCabe, Suzanne; Shaw, Stevan; Jose, Joby; Oliver, Ruth Journal: Clinical pharmacology in drug development Issue: Volume 3:Issue 5(2014:Sep./Oct.) Page Start: 388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. Issue 2 (28th July 2020) Authors: Shah, Mittal; Maroof, Asher; Gikas, Panos; Mittal, Gayatri; Keen, Richard; Baeten, Dominique; Shaw, Stevan; Roberts, Scott J Journal: RMD open Issue: Volume 6:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Issue 8 (8th June 2019) Authors: Glatt, Sophie; Taylor, Peter C; McInnes, Iain B; Schett, Georg; Landewé, Robert; Baeten, Dominique; Ionescu, Lucian; Strimenopoulou, Foteini; Watling, Mark I L; Shaw, Stevan Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 8(2019) Page Start: 1033 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗